Rosen Law Firm Urges Erasca Investors to Consider Leading Securities Fraud Lawsuit
Rosen Law Firm has notified purchasers of Erasca, Inc. common stock of an important lead plaintiff deadline concerning alleged securities law violations by the company.
New York, NY – July 22, 2026 – The law firm Rosen Law Firm has reminded purchasers of Erasca, Inc. (NASDAQ: ERAS) common stock, acquired between January 14, 2025, and April 26, 2026, inclusive, of a critical lead plaintiff filing deadline of August 10, 2026.
The lawsuit alleges that Erasca, Inc., along with its Chief Executive Officer and Chief Financial Officer, violated federal securities laws. Specifically, the complaint claims that the company made false and misleading statements regarding its lead oncology drug candidate, ERAS-0015.
According to the allegations, Erasca repeatedly promoted ERAS-0015 as a potential "best-in-class" therapy. The company is also accused of highlighting superior preclinical results compared to Revolution Medicines' competing drug candidate, RMC-6236, while failing to disclose that these comparisons were allegedly improper and exposed Erasca to patent and trade secret disputes.
Rosen Law Firm stated that investors who purchased Erasca stock during the specified class period may be entitled to compensation without any out-of-pocket fees on a contingency fee basis. The firm is encouraging investors to select experienced counsel and noted that any individual wishing to serve as lead plaintiff must move the Court no later than August 10, 2026.